title: LAU-0901, a novel platelet-activating factor antagonist, is highly neuroprotective in cerebral ischemia.
abstract: Platelet-activating factor (PAF) is a bioactive phospholipid that accumulates during ischemia-reperfusion and is involved in the activation of platelets, neutrophils, and pro-inflammatory signaling. PAF has been suggested to enhance brain ischemia-reperfusion damage. LAU-0901, a novel PAF receptor antagonist, was examined in models of focal cerebral ischemia in rats and mice. Sprague-Dawley rats were anesthetized and received 2-hour middle cerebral artery occlusion (MCAo) by intraluminal suture. LAU-0901 (30, 60, 90 mg/kg; n=9-11) or vehicle (n=11) was administered i.p. at 2 h after onset of MCAo. The neurological status was evaluated at 60 min, and on days 1, 2, 3 and 7 after MCAo. In the dose-response study in mice, C57BL/6 mice were anesthetized and received 1 h MCAo by intraluminal suture. LAU-0901 (15, 30, 60 mg/kg; n=7-9) or vehicle (n=8) was given i.p. at 1 h after onset of MCAo. Local cerebral blood flow (LCBF) was measured at 1, 2, 4, and 6 h after MCAo in mice. LAU-0901 treated rats showed improved neurological score throughout the 7-day survival period. LAU-0901 treatment (30, 60 and 90 mg/kg) reduced total corrected infarct volume compared to vehicle rats by 76, 88 and 90%, respectively. Mice treated with LAU-0901 (30 and 60 mg/kg) reduced total infarction by 29% and 66%, respectively. LCBF was improved by treatment with LAU-0901 (30 mg/kg) by 77% of baseline at 6 h. In conclusion, we demonstrate for the first time that LAU-0901 improves behavioral scores, LCBF and reduces infarct volume after focal cerebral ischemia in rats and mice. Thus, this PAF receptor antagonist exhibits potent and sustained neuroprotection that may be of value for the design of stroke therapies.
authors.affiliation: Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA. lbelay@lsuhsc.edu
authors.forename: Ludmila
authors.initials: L
authors.lastname: Belayev
authors.forename: Larissa
authors.initials: L
authors.lastname: Khoutorova
authors.forename: Kristal
authors.initials: K
authors.lastname: Atkins
authors.forename: William C
authors.initials: WC
authors.lastname: Gordon
authors.forename: Julio
authors.initials: J
authors.lastname: Alvarez-Builla
authors.forename: Nicolas G
authors.initials: NG
authors.lastname: Bazan
mesh_terms: D000208:Acute Disease; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002545:Brain Ischemia / Q000188:drug therapy* / Q000473:pathology; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004095:Dihydropyridines / Q000737:chemistry / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D019579:Neocortex / Q000098:blood supply / Q000473:pathology; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D004095:Dihydropyridines; C487837:LAU 0901; D018696:Neuroprotective Agents; D010972:Platelet Activating Factor
references.citation: Neurosci Lett. 2007 Oct 9;426(1):59-63
references.pmid: 17881124
references.citation: Can J Cardiol. 2000 Apr;16(4):497-504
references.pmid: 10787465
references.citation: Brain Res. 2007 Apr 27;1143:193-8
references.pmid: 17320823
references.citation: Neuroreport. 2007 Jan 22;18(2):115-9
references.pmid: 17301674
references.citation: Ann N Y Acad Sci. 2005 Aug;1053:455-6
references.pmid: 16179552
references.citation: Nephrol Dial Transplant. 2001 Apr;16(4):735-41
references.pmid: 11274266
references.citation: Stroke. 2001 Nov;32(11):2675-81
references.pmid: 11692033
references.citation: Stroke. 1996 Jun;27(6):1112-7
references.pmid: 8650723
references.citation: Invest Ophthalmol Vis Sci. 2006 Mar;47(3):883-91
references.pmid: 16505020
references.citation: J Cereb Blood Flow Metab. 1987 Dec;7(6):729-38
references.pmid: 3693428
references.citation: Mol Neurobiol. 2005 Aug;32(1):89-103
references.pmid: 16077186
references.citation: J Neurophysiol. 2002 Jun;87(6):2851-7
references.pmid: 12037188
references.citation: J Neurosurg. 2000 Jan;92(1):91-9
references.pmid: 10616087
references.citation: J Biol Chem. 2003 Oct 31;278(44):43807-17
references.pmid: 12923200
references.citation: Am J Med. 2000 Sep;109(4):315-23
references.pmid: 10996583
references.citation: Exp Eye Res. 2005 Dec;81(6):742-50
references.pmid: 15979612
references.citation: J Lipid Res. 2003 Dec;44(12):2221-33
references.pmid: 13130128
references.citation: Stroke. 1989 Jan;20(1):84-91
references.pmid: 2643202
references.citation: Stroke. 1986 May-Jun;17(3):472-6
references.pmid: 3715945
references.citation: Ann Neurol. 2006 Mar;59(3):467-77
references.pmid: 16453316
references.citation: J Biol Chem. 1999 Mar 5;274(10):6493-8
references.pmid: 10037742
references.citation: Metab Brain Dis. 1997 Sep;12(3):237-49
references.pmid: 9346472
references.citation: Prostaglandins Other Lipid Mediat. 2005 Sep;77(1-4):65-76
references.pmid: 16099392
references.citation: Int J Angiol. 2001 Jan;10(1):10-14
references.pmid: 11178779
references.citation: Stroke. 2003 Mar;34(3):758-63
references.pmid: 12624304
references.citation: Ann N Y Acad Sci. 1989;559:340-51
references.pmid: 2774404
references.citation: Stroke. 1989 Oct;20(10):1383-90
references.pmid: 2799870
references.citation: Indian J Exp Biol. 2006 Nov;44(11):886-91
references.pmid: 17205708
references.citation: Proc Natl Acad Sci U S A. 1995 May 23;92(11):5047-51
references.pmid: 7761446
references.citation: Nature. 1994 Jan 13;367(6459):175-9
references.pmid: 8114914
references.citation: Stroke. 1998 Feb;29(2):529-34
references.pmid: 9472901
references.citation: Stroke. 1996 Sep;27(9):1616-22; discussion 1623
references.pmid: 8784138
references.citation: Br J Pharmacol. 2003 Jun;139(4):733-40
references.pmid: 12812996